A phase three global clinical trial led by the Murdoch Children's Research Institute (MCRI) has shown a new drug boosts bone growth in children born with achondroplasia, the most common type of dwarfism.
The randomised, double-blind, placebo-controlled trial results, led by MCRI clinical